JIMD Reports · 2020 · 10 citations · 31 references
MedicineNeurologyNeuroscienceNeurogeneticsNeuropathologyPediatric NeurologyAmino Acid Metabolism DisordersCerebral PalsyDevelopmental NeurologyNeurodevelopmental DisordersNeurogenetic DisordersPediatric Neurologic DisordersAutosomal Recessive InheritanceCompound Heterozygosity AnalysisDyskinetic Cerebral PalsyDystonia SyndromesPathogenic Variant DetectionPediatric Dystonia GeneticsPediatric Neurogenetic DisordersTryptophan Metabolism
Abstract A 4‐year‐old girl was referred for reassessment of dyskinetic cerebral palsy. Initial investigations in her country of birth, India, had not yielded a diagnosis. MRI brain in infancy revealed bilateral putamen hyperintensity. She had generalized dyskinesia predominantly bulbar and limbs. Motor and speech development were most affected with preservation of cognitive development. There was no history of acute encephalopathic crisis or status dystonicus. Initial urine organic acids and amino acids and acylcarnitine profile (ACP) were normal. A dystonia genetic panel showed compound heterozygosity with a pathogenic variant and a variant of uncertain significance in the GCDH gene. The latter is hitherto undescribed and is indicative of a potential diagnosis of glutaric aciduria type 1 (alternatively glutaric acidemia type 1) (GA‐1), an autosomal recessive disorder of mitochondrial lysine/hydroxylysine and tryptophan metabolism. Repeat urine organic acids showed isolated slightly increased 3‐hydroxy glutarate excretion consistent with GA‐1 and characterizing the patient as a “low excretor,” a diagnostic sub‐group where diagnosis is more challenging but prognosis is similar. Repeat MRI Brain at age 4 showed volume loss and symmetric T2 hyperintensity in the posterior putamina bilaterally. This case highlights the diagnostic dilemma of GA‐1 where differing clinical courses, genetic variants, neuroradiological findings, and biochemical excretion patterns may lead to a later diagnosis. The presence of newborn screening for GA‐1 should not dull the clinician's suspicion of the possibility that GA‐1 may present with a complex movement disorder. Timely diagnosis and treatment is essential, as neurological sequelae are largely irreversible.
31
Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary
Michael S. Watson, Marie Y. Mann, Michele A. Lloyd-Puryear et al. · PEDIATRICS · 2006 · 501 citations
Medicine, Genetics, Pediatrics +17
Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I
Inga Harting, Eva Neumaier‐Probst, Angelika Seitz et al. · Brain · 2009 · 176 citations
Medicine, Neurology, Neuroscience +17
Therapeutic modulation of cerebral l-lysine metabolism in a mouse model for glutaric aciduria type I
Sven W. Sauer, Silvana Opp, Georg F. Hoffmann et al. · Brain · 2010 · 124 citations · Full text